Vaxchora Market Report 2026

Vaxchora Market Overview

• The Vaxchora market growth in the historic period has been driven by increased international travelendemic regions, rising cholera outbreak preparedness measures • Market expansion is supported by increasing investments in global disease prevention, rising demand for single-dose vaccines • Growth Driver: Impact Of Rising Cholera Incidence On Vaccine Demand • Market Trend: Expanding Regional Approvals To Enhance Cholera Prevention • North America was the largest region in 2025.

What Is Covered Under Vaxchora Market?

Vaxchora is a vaccine used to prevent cholera, an infectious disease caused by the bacterium Vibrio cholerae. It is specifically approved for use in individuals aged 2 years and older traveling to areas where cholera is common. Vaxchora is recommended for adults aged 18 to 64 who are planning to visit regions where cholera is prevalent. The vaccine comes as a single-dose liquid, taken 10 days before potential contact with the bacteria. The main clinical indications in the vaxchora market are prevention of cholera and prevention of gastrointestinal infections caused by vibrio cholerae. Prevention of Cholera refers to the process of avoiding the spread of vibrio cholerae, the bacteria responsible for causing cholera, through vaccination, sanitation, and safe water practices. Vaxchora is an oral vaccine used to prevent cholera by stimulating immunity against vibrio cholerae in individuals traveling to endemic areas. The various distribution channels include hospital pharmacies, retail pharmacies, online pharmacies, and travel pharmacies, and several end users including adult, pediatric, and geriatric.

What Is The Vaxchora Market Growth Forecast?

The growth in the forecast period can be attributed to increasing investments in global disease prevention, rising demand for single-dose vaccines, expansion of travel health services, growing focus on outbreak prevention strategies, increasing adoption in humanitarian and emergency response settings. Major trends in the forecast period include increasing demand for travel-related vaccines, rising awareness of cholera prevention, growing adoption of oral vaccine formats, expansion of global travel immunization programs, enhanced focus on rapid immunization compliance.

Global Vaxchora Market Segmentation

1) By Clinical Indication: Prevention Of Cholera, Prevention Of Gastrointestinal Infections Caused By Vibrio Cholerae 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Travel Clinics 3) By End User: Adult, Pediatric, Geriatric

What Is The Driver Of The Vaxchora Market?

The rise in the incidence of cholera cases is expected to drive the growth of the vaxchora market going forward. Cholera is an infection caused by the vibrio cholerae bacterium, leading to severe diarrhea and dehydration from contaminated water or food. Cholera cases are rising due to factors such as inadequate sanitation, poor access to clean water, climate change, and increased population mobility to cholera-endemic regions. Vaxchora prevents cholera by stimulating the immune system to produce antibodies against Vibrio cholerae serogroup O1, reducing the risk of severe diarrhea and dehydration caused by cholera infection. For instance, in August 2025, according to the UK Health Security Agency UK-based government agency reported that In EWNI, 8 confirmed cholera cases were reported from January to June 2025, up from 1 case during the same period in 2024. Therefore, the rise in the incidence of cholera cases is driving the growth of the vaxchora industry.

Key Players In The Global Vaxchora Market

Major companies operating in the vaxchora market are Bavarian Nordic A/S

Global Vaxchora Market Trends and Insights

The key trend in the vaxchora market is expanded vaccination regional approvals to increase accessibility and cater to the growing demand for cholera prevention in endemic and high-risk areas. Expanded regional approvals help improve public health outcomes through broader immunization coverage and address the ever increasing global need for effective cholera prevention solutions. For example, in September 2024, Bavarian Nordic, a Denmark-based biotechnology company, announced the commercial availability of Vaxchora, the only single-dose oral vaccine approved in Canada to protect against cholera, a sudden and severe intestinal infection marked by acute watery diarrhea. The vaccine is delivered as a single oral dose and protects within 10 days.

What Are Latest Mergers And Acquisitions In The Vaxchora Market?

In May 2023, Bavarian Nordic A/S, a Denmark-based biotechnology company, acquired travel vaccine portfolio from Emergent BioSolutions for $270 million. The acquisition includes two marketed vaccines, Vivotif for typhoid fever and Vaxchora for cholera, and a promising Phase III candidate for chikungunya, addressing critical unmet medical needs. This strategic move aims to strengthen Bavarian Nordic's position in the travel vaccine market while enhancing its research and development capabilities. Emergent BioSolutions is a US-based biotech company developing vaccines, including Vaxchora.

Regional Insights

North America was the largest region in the vaxchora market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Vaxchora Market?

The vaxchora market consists of sales of oral cholera vaccines, vaccine administration supplies, and cold chain equipment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Vaxchora Market Report 2026?

The vaxchora market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the vaxchora industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.